Druggable mutations of genes of the Ras/Raf/MEK/ERK signaling pathway are recurrent in HS in general [39, 40], as illustrated by several cases submitted to the 2016 EAHP workshop on histiocytic neoplasms involving the lymph nodes [35]. The gene discussed is MAP2K7; the disease is histiocytic neoplasm.